ArticleInternational journal of molecular sciences2026
Suppression of Glucosylceramide Synthase Reverses Drug Resistance in Cancer Cells Harboring Homozygous p53 Mutants.
Md Saqline Mostaq, Mohammad N Amin, Amanda Raphael, Celine Asbury, Anish Gupta, Xin Gu, Xianlin Han, Davorka Sekulic, Pawel Michalak, Lin Kang and 1 more
Abstract read
In one paragraphArticle in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
5 · Who and what moneyAuthors and funding
11 authors.
Md Saqline MostaqSchool of Basic Pharmaceutical and Toxicological Sciences, College of Pharmacy, University of Louisiana at Monroe, Monroe, LA 71201, USA.ORCID 0009-0002-2359-4481 Mohammad N AminSchool of Basic Pharmaceutical and Toxicological Sciences, College of Pharmacy, University of Louisiana at Monroe, Monroe, LA 71201, USA.ORCID 0000-0002-8296-3542 Amanda RaphaelSchool of Basic Pharmaceutical and Toxicological Sciences, College of Pharmacy, University of Louisiana at Monroe, Monroe, LA 71201, USA.
Celine AsburyDivision of Biomedical Affairs and Research, Edward Via College of Osteopathic Medicine, Monroe, LA 71203, USA.
Anish GuptaDivision of Biomedical Affairs and Research, Edward Via College of Osteopathic Medicine, Monroe, LA 71203, USA.
Xin GuDepartment of Pathology, Louisiana State University Health Sciences Center, Shreveport, LA 70112, USA.
Xianlin HanBarshop Institute for Longevity and Aging Studies, University of Texas Health Science Center, San Antonio, TX 78229, USA.ORCID 0000-0002-8615-2413 Davorka SekulicGlobal Medical Affairs, RD Hematology, Sanofi, Cambridge, MA 02139, USA.
Pawel MichalakDivision of Biomedical Affairs and Research, Edward Via College of Osteopathic Medicine, Monroe, LA 71203, USA.
Lin KangDivision of Biomedical Affairs and Research, Edward Via College of Osteopathic Medicine, Monroe, LA 71203, USA.
Yong-Yu LiuSchool of Basic Pharmaceutical and Toxicological Sciences, College of Pharmacy, University of Louisiana at Monroe, Monroe, LA 71201, USA.ORCID 0000-0002-7968-0162 Funding
Ceramide glycosylation determines the stemness of cancer stem cellsR15CA167476 · NCI · UNIVERSITY OF LOUISIANA AT MONROE · PI LIU, YONG-YU · 2013 to 2013
$413kNCI NIH HHS R15CA167476NIH HHS 8P20GM103424-21
6 · The paper itselfAbstract
Glucosylceramide synthase (GCS) catalyzes ceramide glycosylation in response to cell stress that produces glucosylceramide and other glycosphingolipids. GCS overexpression is a cause of drug resistance and enriches cancer stem cells (CSCs) during cancer chemotherapy. Previous studies showed that GCS modulates the expression of p53 mutants and oncogenic gain-of-function (GOF) in heterozygous knock-in cell models (
Indexed as
Drug Resistance, NeoplasmGlucosyltransferasesMutationTumor Suppressor Protein p53AnimalsAntineoplastic AgentsCell Line, TumorGene Expression Regulation, NeoplasticHomozygoteHumansMiceNeoplastic Stem CellsOxaliplatinPaclitaxelAntineoplastic Agentsceramide glucosyltransferaseGlucosyltransferasesOxaliplatinPaclitaxelTP53 protein, humanTumor Suppressor Protein p53cancer stem cellsdrug resistanceglucosylceramide synthasemissense mutationN6-methyladenosinep53 tumor suppressorRNA modification
Identifiers
PMID41977417
PMCPMC13073438
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390